

Table SI. List of primary antibodies used in this study.

Antibody target	Dilution	Cat. no.	Supplier
Chromogranin	1:200	238M-96	Cell Marque; MilliporeSigma
Synaptophysin	1:100	PA0299	Novocastra Laboratories, Ltd.; Leica Biosystems
p40	1:100	ACI 3030 A,B	Biocare Medical, LCC
p63	1:80	PA0103	Novocastra Laboratories, Ltd.; Leica Biosystems
MLH1	1:25	PA0988	Novocastra Laboratories, Ltd.; Leica Biosystems
MSH2	1:200	286M-14	Cell Marque; MilliporeSigma
MSH6	1:200	287M-14	Cell Marque; MilliporeSigma
PMS2	1:100	288M-14	Cell Marque; MilliporeSigma
p53	1:500	M7001	Dako; Agilent Technologies, Inc
E-cadherin	RTU	PA0387	Novocastra Laboratories, Ltd.; Leica Biosystems
PD-L1	RTU	741-4905	Ventana Medical Systems; Roche Tissue Diagnostics;
PD-1	1:200	315M-94	Cell Marque; MilliporeSigma
HER2	RTU	790-4493	Ventana Medical Systems; Roche Tissue Diagnostics

MLH1, mutL homolog 1; MSH2, mutS homolog 2; MSH6, mutS homolog 6; PMS2, postmeiotic segregation increased 2; PD-L1, programmed Cell Death Ligand 1; PD-1, Programmed Cell Death Protein 1; HER2, human epidermal growth factor receptor 2; RTU, ready-to-use.